The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 358:2746-2747 June 19, 2008 Number 25
NextNext

Imatinib as a Possible Cause of Severe Rhabdomyolysis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: Imatinib mesylate (Gleevec [Glivec], Novartis), a protein kinase inhibitor of c-kit receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor {alpha} (PGFR-{alpha}), is widely used for the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors. Its common side effects (diarrhea, edema, asthenia, myalgia, and skin reactions) are most often mild and manageable.1

We describe the case of a 25-year-old woman who received imatinib mesylate (at a daily dose of 400 mg) in a clinical trial for the treatment of aggressive fibromatosis (desmoid tumors) not amenable to surgery.2 Shortly after the initiation of treatment with imatinib, she . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.